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Alzheimer’s disease (AD) is a devastating disorder of increasing prevalence in modern
society. Mild cognitive impairment (MCI) is considered a transitional stage between
normal aging and AD; however, not all subjects with MCI progress to AD. Prediction of
conversion to AD at an early stage would enable an earlier, and potentially more effective,
treatment of AD. Electroencephalography (EEG) biomarkers would provide a non-invasive
and relatively cheap screening tool to predict conversion to AD; however, traditional EEG
biomarkers have not been considered accurate enough to be useful in clinical practice.
Here, we aim to combine the information from multiple EEG biomarkers into a diagnostic
classification index in order to improve the accuracy of predicting conversion from MCI
to AD within a 2-year period. We followed 86 patients initially diagnosed with MCI for 2
years during which 25 patients converted to AD. We show that multiple EEG biomarkers
mainly related to activity in the beta-frequency range (13–30Hz) can predict conversion
from MCI to AD. Importantly, by integrating six EEG biomarkers into a diagnostic index
using logistic regression the prediction improved compared with the classification using
the individual biomarkers, with a sensitivity of 88% and specificity of 82%, compared
with a sensitivity of 64% and specificity of 62% of the best individual biomarker in this
index. In order to identify this diagnostic index we developed a data mining approach
implemented in the Neurophysiological Biomarker Toolbox (http://www.nbtwiki.net/). We
suggest that this approach can be used to identify optimal combinations of biomarkers
(integrative biomarkers) also in other modalities. Potentially, these integrative biomarkers
could be more sensitive to disease progression and response to therapeutic intervention.
Keywords: Neurophysiological Biomarkers, Alzheimer’s disease, mild cognitive impairment (MCI),
electroencephalography, predictive analysis, time series analysis, eyes closed resting state
INTRODUCTION
Caused by an increasing average age of the population in the
developed world, dementia is becoming a major healthcare prob-
lem. Alzheimer’s disease is the most common form of dementia
and the golden standard for diagnosis is the post-mortem iden-
tification of Amyloid Beta 42 depositions and tangles (Blennow
et al., 2006; Herrup, 2010). It has been suggested that Alzheimer’s
disease begins years, maybe even decades before actual cognitive
symptoms appear (Sperling et al., 2011). However, normal age-
ing is also characterized by a slow decline of cognitive functions,
which means it can be difficult to disentangle normal ageing from
Alzheimer at a very early stage.
Patients with mild cognitive impairment (MCI) are at high
risk of developing Alzheimer’s disease. The label MCI is given
when there is a cognitive complaint (mostly memory), which can
also be demonstrated on formal testing, while general cognitive
functioning is relatively intact and a patient is still living inde-
pendently (Flicker et al., 1991; Gauthier et al., 2006; Albert et al.,
2011). Therapies that stop the conversion to Alzheimer’s disease
unfortunately remain to be developed, but it is likely that these
drugs or therapies will appear in the future (Prins et al., 2010;
Huang and Mucke, 2012). It is plausible that these therapies will
be most effective before major brain damage has occurred and
it is, therefore, important to develop biomarkers sensitive of this
very early stage (Sperling et al., 2011). Early-stage identification
may also help the development of new treatments that are more
effective at this stage as it can facilitate monitoring of the response
to the intervention.
We here focus on biomarkers obtained from electroen-
cephalography (EEG) recordings in the eyes-closed resting state
(ECR). EEG biomarkers are optimal for screening purposes
because the EEG recording can be obtained using relative cheap
and non-invasive equipment, which is widely available and fast to
use. Several previous EEG studies of conversion from mild cog-
nitive impairment to Alzheimer’s disease have been conducted
(Jelic et al., 1996, 2000; Huang et al., 2000; Stam et al., 2003;
Schoonenboom et al., 2004; Rombouts et al., 2005; Babiloni et al.,
2006, 2011; Kwak, 2006; Rossini et al., 2006, 2008; Lehmann
et al., 2007; Moretti et al., 2007a,b, 2008, 2011; Luckhaus et al.,
2008) mainly using biomarkers such as spectral measures and
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synchronization between brain regions. Machine-learning tech-
niques have been used to explore differences between MCI and
AD with varying success (Huang et al., 2000; Bennys et al., 2001;
Prichep et al., 2006; Buscema et al., 2007; Lehmann et al., 2007;
Prichep, 2007; Rossini et al., 2008), however, only few studies have
tried to predict the conversion from MCI to AD (Prichep et al.,
2006; Prichep, 2007; Antila et al., 2013). Many studies typically
focus on a small number of biomarkers (on the order of 15marker
values), and some do not have adequate validation of their results
on independent groups. We perform large-scale data mining of
multiple biomarkers (Figure 1A) and validate our results on an
independent group of subjects.
Our focus is on the EEG measured as part of the initial hospi-
tal intake test, combined with longitudinal recordings measured 1
year after the initial intake test. We have mapped several classical
EEG biomarkers, such as frequency and power, but also non-
classical biomarkers such as detrended fluctuation analysis and
oscillation burst analysis (Poil et al., 2008; Montez et al., 2009).
By combining several biomarkers, it is often possible to find better
separation boundaries between two groups (Figure 1C), because
FIGURE 1 | An integrative approach toward improved prediction of
mild cognitive impairment to Alzheimer’s disease conversion. (A)
Diagram of processing flow. We calculate biomarkers on the second year
EEG recording; hereafter we mapped all potential differences between MCI
and AD using Student’s t-test (Difference map). Next, we performed logistic
regression on each single biomarker. Biomarkers with best
single-classification power were seeded to a genetic search algorithm; this
algorithm further optimized the combined biomarker set. This biomarker set
was then used to predict MCI to AD conversion based on the first-year EEG
recording. To evaluate the lower bound on the classification, half-split
cross-validation was performed. Finally, the outcome performance was
evaluated on the 1st EEG recording. (B) Overview of how the MCI patient
cohort splits into AD, another diagnosis, or remain MCI one or 2 years after
the in-take. (C) The integration of multiple biomarkers can reveal hidden
separation boundaries. Here, we show two simulated biomarkers where
the red and blue groups are overlapping if we only consider the single
biomarkers. By combining the biomarkers, we see a clear separation
boundary at the diagonal. Classification algorithms aim to identify this
boundary, and use it to predict group association for new data.
each biomarker gives additional information (Lehmann et al.,
2007). In this longitudinal study we show that EEG biomarkers
from the initial hospital in-take test retrospectively can be used
in a classifier algorithm to predict the diagnosis that the patient
obtained within the subsequent 2 years.
METHODS AND MATERIALS
SUBJECTS
The study involved 86 mild cognitive impairment (MCI) subjects
who were referred to the Alzheimer Center at the VU University
Medical Center in Amsterdam, the Netherlands (Figure 1B).
Upon the first visit at the Alzheimer Center, all subjects under-
went a thorough 1-day examination consisting of history taking,
physical, and neurological assessment, neuropsychological testing
including the Mini Mental State Examination (MMSE) (Folstein
et al., 1975), laboratory tests, structural magnetic resonance imag-
ing (MRI), and a routine electroencephalogram (EEG). After
reviewing the clinical and ancillary imaging data, a multidisci-
plinary team established a consensus-based final diagnosis for
each patient. The initial diagnosis of MCI was based on the cri-
teria set by (Petersen et al., 1999), consisting of (a) objective
memory impairment as seen during neuropsychological evalua-
tion, defined by performances≥ 1.5 standard deviation below the
mean value of education—and that of age matched controls, (b)
normal activities of daily living, and (c) a rating score of 0.5 in
clinical dementia (Hughes et al., 1982).
All MCI subjects were followed up clinically during an average
period of 709 ± [537:779] days (1.9 years) (median ± 95% con-
fidence interval). The clinical follow up included medical history
and functional status assessment re-examination in order to mea-
sure potential changes in the cognitive domain. MCI subjects who
showed steady or enhanced cognitive functioning (but still ful-
filled the criteria for MCI) during re-assessment were considered
as MCI-stable, while MCI subjects who showed impoverished
cognitive functioning, and fulfilled the NINDS-ADRDA criteria
(McKhann et al., 1984) to be diagnosed with Alzheimer’s disease,
were considered to belong to the AD-converter group. Exclusion
criteria were previous head trauma, history of neurological or
psychiatric disease or use of psychotropic medications. Patients
progressing fromMCI to other disorders than Alzheimer’s disease
(n = 22) were excluded from the analyses reported here. These
patients progressed to; “Subjective complaints” (n = 9), possible
Alzheimer’s disease (n = 1), frontal lobe dementia (n = 1), vas-
cular dementia (n = 3), Lewy body dementia (n = 1), dementia
other (n = 2), psychiatric (n = 2), or another neurological dis-
order (n = 3). The measurements were approved by the Ethics
Committee of the VU University Medical Center, and were in
accordance to the Helsinki declaration. All subjects signed an
informed consent.
EEG RECORDINGS
Twenty-one channel EEGs were recorded in a sound attenuated,
electrically shielded, and dimly lit room. These recordings were
performed with OSG digital equipment (Brainlab®) at the follow-
ing locations of the international 10–20 system: Fp2, Fp1, FT9,
FT10, F8, F7, F4, F3, A2, A1, T4, T3, C4, C3, T6, T5, P4, P3, O2,
O1, Fz, Cz, and Pz. The recording was referenced to the common
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average of all electrodes, excluding Fp1 and Fp2. Sampling fre-
quency was 500Hz and analogue-digital precision was 16 bit. The
impedance of all electrodes was less than 5 k. Recordings were
made with a 70Hz low-pass filter (time constant 1 s). Subjects sat
in a reclined chair for approximately 20min. During this period
the subjects kept their eyes closed most of the time, however,
at irregular intervals, they were asked to open their eyes when
drowsiness was noticed. Approximately 15min into the record-
ing a memory task, which consisted of remembering pictogram
images for 1min was performed.
EEG CLEANING
The recordings during task and eyes-open were not analyzed.
The EEG was viewed in windows of 5 s, and sharp transient arti-
facts were cut out. On average 17.8 [range (12.4:24.1)] minutes
of eyes-closed rest EEG was left. The JADE ICA algorithm was
then used to separate the signal into 23 components (Cardoso
and Souloumiac, 1993). Eye movements, eye blinks, muscle arti-
facts, and heartbeat components were rejected, based on abnor-
mal topography, component activation, activity distribution, and
spectrum.
BIOMARKERS AND PROCESSING FLOW
The Neurophysiological Biomarker Toolbox (NBT) (http://www.
nbtwiki.net/) was used to organize, analyse, and calculate all
biomarkers in this study (Hardstone et al., 2012). An EEG
biomarker is a quantitative measure derived from the EEG, e.g.,
the dominant frequency of the beta frequency band (13–30Hz),
to be used as a diagnostic or prognostic predictor of disease
(Figure 2).
We extracted 177 biomarkers from each EEG trace.We decided
to focus on biomarkers we have had good experiences with in
other studies, and acknowledge thatmanymore biomarkers could
have been selected.
Based on the broadband signal, we computed 28 biomark-
ers, namely: Hjorth’s activity, mobility and complexity parame-
ters (Hjorth, 1970); Time domain Parameters (Goncharova and
Barlow, 1990), Wackermann’s global field strength, global fre-
quency, and spatial complexity (Wackermann, 1999), Barlow’s
amplitude, frequency and spectral purity (Goncharova and
Barlow, 1990). Alpha peak frequency, peak width, power cor-
rected for 1/f baseline (Poil et al., 2011), when applicable the
same parameters where found for double alpha peaks. Alpha-
theta transition point (Klimesch, 1999), Beta peak frequency
(Figure 2), width, power corrected for 1/f baseline (Van Aerde
et al., 2009), same for second beta peak if present; Frequency
stability was evaluated using different methods, by the standard
deviation and interquartile range of the central frequency and
maximum wavelet frequency calculated in windows, and by, the
distribution parameters of the phase values above zero, and of the
number of oscillation cycle peaks per window.
For each of the classical frequency bands—delta (1–3Hz),
theta (4–7Hz), alpha (8–13Hz), beta (13–30Hz), and gamma
(30–45Hz)—we computed 13 biomarkers; namely: The ampli-
tude envelope was extracted using Hilbert transform and char-
acterized extensively. We calculated the spearman correlations
of amplitude envelopes in different channels. The distribution
FIGURE 2 | An EEG biomarker is a quantitative measure derived from
the EEG. For example the Beta peak frequency. (A) Time-frequency
(TF-plot) plot of 6 s of an eyes-closed rest EEG signal (from Pz) (Wavelet).
The color shows the power. Low-amplitude bursts in the beta-frequency
band (13–30Hz) not directly coupled with the strong alpha are observed.
(B) The raw EEG signal used to calculate the TF-plot in (A). Clear and strong
alpha (8–13Hz) oscillations are observed. (C) Zooming in, we observe small
peaks in the space between the strong alpha oscillation peaks, which
correspond to the beta oscillations. (D) The power spectrum of the
full-length EEG signal reveals a beta peak (left). To find the beta peak we
first fit a 1/f baseline (right), next we fit a Gaussian to the small beta peak.
We now have four biomarkers; Beta peak frequency, Beta peak width, Beta
peak corrected power (i.e., minus 1/f baseline), and peak uncorrected
power.
of amplitude values was characterized by kurtosis, skewness,
interquartile range, median, range, and variance. Furthermore,
detrended fluctuation analysis characterizing long-range tempo-
ral correlations (Linkenkaer-Hansen et al., 2001; Hardstone et al.,
2012; Poil et al., 2012), multifractality spectral width (Kantelhardt
et al., 2002; Ihlen, 2012) and oscillation bursts 95th percentile
durations and sizes (Montez et al., 2009; Poil et al., 2011) were
calculated on the amplitude envelope. The instantaneous phase
was also extracted using Hilbert transform, and the 95th per-
centile duration and size of the stable phase bursts (a phase
bursts is defined as the period between phase slips) were cal-
culated. In addition, we computed for all frequency bands and
individualized frequency bands, defined as Alpha1 (APF = indi-
vidually defined Alpha peak frequency): (APF–4 to APF–2) Hz,
Alpha2: (APF–2 to APF) Hz, Alpha3: (APF to APF+2) Hz;
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Beta: (APF+2 to 30) Hz (Klimesch, 1999), 7 biomarkers: abso-
lute, relative power, and power ratios, furthermore, the central
frequency, power in central frequency, bandwidth and spec-
tral edge (Vural and Yildiz, 2010; O’Gorman et al., 2013). In
total, we extracted 177 biomarker values from each EEG trace
(Table 1).
Next, we performed data mining on these biomarkers based
on the second EEG recording (Figure 1A), to identify biomarkers
that reached a significance level of p < 0.05 (student’s t-test) for
the comparison of stable MCI vs. AD-converters (based on the
diagnosis after 2 years). We here use student’s t-test because this
test has best statistical power in most cases under the assumption
of normal distributed biomarker values. The biomarkers were
tested per channel, and a binomial multiple-comparison correc-
tion was performed (Poil et al., 2011). The binomial multiple-
comparison correction tests whether a significant number of
channels are found (i.e., 3 or more channels, p < 0.05). The per-
formance of two different classification algorithms (see below for
details) in integrating significant biomarkers into a diagnostic
index was then tested using their median values across significant
channels.
DEVELOPMENT OF A DIAGNOSTICS INDEX
Tomove beyond single-biomarker classification we aimed to inte-
grate several EEG biomarkers in a diagnostic index that would
classify the AD-converter group from theMCI-stable group better
than each individual biomarker. Using one dataset for develop-
ment and testing is not recommended, because it is theoretically
possible to find a perfect separation of two groups if enough
biomarkers are included (so-called over-fitting). To counteract
this issue we build our classification model based on the sec-
ond EEG recording (which was obtained in 34 out of a total of
64 subjects that were either MCI-stable or AD-converters), and
tested the classification accuracy retrospectively on the first EEG
recording. Thirty subjects were not included in the training (22
MCI-stable, 8 AD-converters), because these subjects did not have
any second-year recording. These subjects serve as our ultimate
classification test. We also used half-split cross-validation to
evaluate the stability and lower bound of the solution (see below).
STATISTICS: LOGISTIC REGRESSION WITH GENETIC SEARCH
Binary classification was performed using logistic regression.
In logistics regression the binary outcome either AD-converter
(1) or MCI-stable (0) is regressed with a linear combination
of biomarkers. More specifically we fit a function f (z) using
maximum likelihood.
f (z) = 1
1 + e−z
with
z = β0 +
k∑
i=1
βi xi, (1)
and x are the k biomarkers included in the regression (included
as medians across significant channels), and βi are the regres-
sion coefficients. The function f represents the probability
of Alzheimer’s disease. We use the 50% probability as our
classification threshold, i.e., if f ≥ 0.5, the patient belong to
the AD-converter group, otherwise the patient belongs to the
MCI-stable group. We used a genetic search method to identify
biomarkers that combined (using logistic regression) would
give the best classification of the outcome MCI-stable vs. AD-
converters. Genetic search is considered an efficient method
for searching large data sets, instead of the computationally
demanding alternative of testing all possible combinations (Koza
and Poli, 2005; Zviling et al., 2005). The genetic approach is
based around an evolutionary idea where the combined set of
biomarkers is “mutated” by different mutation rules; addition of
a random biomarker, removal of a biomarker, random selection
of a new set of four biomarkers, and random substitution of a
biomarker. Each rule was applied 5 times in each generation,
leading to 20 new sets of biomarkers. The classifications of these
new sets were then compared with the previous optimal set. Only
the best biomarker set survived and was used as the base for next
generation of mutations. We did not set limits on the maximum
or minimum number of biomarkers in each set.
The genetic algorithm was seeded with an initial set of five
biomarkers with the highest Matthew correlation coefficient (see
outcome evaluation below). The genetic algorithm ran for 100
Table 1 | Thirty-five biomarkers from different signal processing domains were extracted.
Spatial biomarkers Temporal biomarkers Spectral biomarkers
Spearman correlations of the amplitude
envelope across channels
Detrended fluctuation analysis
Multifractal spectral width
Oscillation bursts duration and size
Stable phase bursts duration and size
Frequency stability; standard deviation,
interquartile range of central frequency,
maximum wavelet frequency; distribution
parameters of the phase values above zero;
number of oscillation cycles per window
Amplitude envelope parameters; kurtosis,
skewness, interquartile range, median, range,
and variance
Absolute and relative power
Central frequency
Power in central frequency
Bandwidth and spectral edge
Hjorth’s activity, complexity, and mobility
Wackerman’s Global Field strength, global
frequency, and spatial complexity
Barlow’s amplitude, frequency, and spectral purity
Alpha peak frequency, peak width
Alpha peak power corrected for 1/f baseline
Beta peak frequency, peak width
Beta peak power corrected for 1/f baseline
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generations. At each generation the biomarker set with maximal
positive likelihood ratio (see outcome evaluation below) survived.
In all cases the logistic regression model was fitted using the sec-
ond EEG recording, and the classification outcome was measured
using the first EEG recording.
STATISTICS: ELASTIC NET LOGISTIC REGRESSION
As an alternative to genetic optimization of biomarkers included
in the logistic regression, we employed an elastic net logistic
regression algorithm (Zou and Hastie, 2005) as implemented in
the GLMnet package for Matlab (http://www-stat.stanford.edu/
~tibs/glmnet-matlab/) (Friedman et al., 2010). This algorithm
promises a build-in selection of features that optimally can per-
form much better than the less stable genetic optimization. The
elastic net optimizes the number of biomarkers included in the
diagnostic index by minimizing both the L1 and L2 norm of the
regression coefficients by minimizing the equation
L (λ1,λ2, β) = |z − Xβ|2 + λ1 |β| + λ2 |β|2
where the first term is similar to the logistic regression, and the
second and third are the penalizing terms (the elastic net) (Zou
and Hastie, 2005). The parameters λ1 and λ2 determines the
influence of either the L1 or L2 norm penalty. We define a new
combined parameter
α = λ2
λ1 + λ2
which we optimized in 5-split cross-validation based on the best
classification by training on second-year data, and testing on the
1/5 left-out subject group on first-year EEG (note that subjects
which did not have a second-year EEG were not included, and,
therefore, serve as our ultimate test group (see Results) (data not
shown). We found the best classification with α = 0.8.
STATISTICS: CLASSIFICATION OUTCOME EVALUATION
To evaluate the outcome of our classification we use five different
measures:
• Sensitivity (SE): defined as the (number of correctly classified
AD-converter patients)/(number of AD-converter patients).
• Specificity (SP): defined as the (number of correctly classified
MCI-stable subjects)/(number of MCI-stable subjects).
• Positive predictive value (PPV): defined as (number of cor-
rectly classified AD-converter patients)/(number of patients
classified as AD-converters).
• Positive likelihood ratio (PLR): defined as (Sensitivity)/
(1-Specificity).
• Matthew correlation coefficient (MCC): explains the correla-
tion between the outcome and the expected outcome (Baldi
et al., 2000).
A Matthew correlation coefficient higher than 0.20, sensitivity
higher than 65%, specificity higher than 65%, positive predictive
value higher than 65%, and a positive likelihood ratio higher than
1.6 means that the classification is significantly different from a
random classification (Monte Carlo simulation, 5000 iterations,
n = 65, note these results depends on the sample size making the
threshold levels lower for larger sample sizes, p < 0.05). Perfect
classification would give aMatthew correlation coefficient (MCC)
of 1, sensitivity of 100%, specificity of 100%, positive predictive
value of 100%, and an infinite positive likelihood ratio.
An issue with these outcome measures is that they only tell
how well the classification fits the given subgroup of subjects,
but not how well the classification generalizes to other subject
populations. We counteract this by three approaches; (1) classi-
fication was performed on the second EEG recording, whereas
the prediction was tested on the first EEG recording, (2) as the
ultimate test we evaluated the prediction on subjects not included
for classifier training (because not all subjects had a second EEG
recording), and (3) we performed a half-split cross-validation. In
the half-split cross-validation the sample was divided randomly
in half several times (1000 iterations); the classifier was then
trained on the first half, and the outcome was evaluated on the
second half. We report the median outcome measures over these
splits. Cross-validation gives an estimate of the classification
performance on an “unknown” sample (Witten et al., 2011).
However, cross-validation also suffers from lower n numbers,
which means their outcome should be viewed as a conservative
estimate of the average outcome.
STATISTICS: GROUP DIFFERENCES AND CORRELATIONS
We use non-parametric permutation tests based on median
(Box and Andersen, 1955; Ernst, 2004) to test for differences
between groups. Non-parametric tests are more robust toward
non-normal data, but also often have lower power than paramet-
ric such as student’s t-test. Confidence intervals (95%)were found
using non-parametric bias corrected and accelerated bootstrap
(n = 5000) (DiCiccio and Efron, 1996).
STATISTICS: 2× 2 TABLE INDEPENDENCE TESTS
To test for dependence of genotype, gender, and patient group
we used Barnard’s exact test, which is appropriate for low sam-
ple statistics compared with Chi-square test, and has better power
compared with Fisher’s exact test (Barnard, 1947).
STATISTICS: MULTIPLE COMPARISONS
Because we do large-scale mapping of biomarkers, we employ a
lenient approach to multiple comparisons correction at the first
level of analysis. This means that in the initial mapping of poten-
tial difference between the stable MCI and AD-converter groups,
we only perform a binomial correction for the number of signif-
icant channels in each biomarker (Poil et al., 2011). We do not
correct the p-values across different biomarkers. This approach is
appropriate since this mapping of potential difference is only used
to identify candidate biomarkers for the genetic search algorithm.
RESULTS
PATIENT GROUPS—AGE AND GENDER
Initially 86 subjects (Age: 68.7 [66.5:71.3] years, median [95%
confidence interval], age at first EEG, 58 males) were diagnosed
with mild cognitive impairment (MCI). After 415 ± [393:478]
days, 17 patients (9 males) had converted to Alzheimer’s dis-
ease. After 709 ± [537:779] days (1.9 years) a total of 25 patients
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(14 males) had converted to AD (Age: 69 ± [67:72] years), 39
subjects (28 males) remained MCI (Age: 67 ± [65:71] years),
9 subjects (6 males) were diagnosed with subjective complaints
(Age: 67 ± [46:73] years), and 13 patients (10 males) with
other disorders (Age: 70 ± [61:74] years) (including frontal lobe
and Vascular dementia). No significant difference was found
in age and gender between stable MCI and AD-converters
(Gender: Barnard’s test, p = 0.16; Age: permutation test, p =
0.49) (Table 1). We only focus on the patients diagnosed with AD,
and subjects remaining stable MCI. In the following we use the
last diagnosis of the subjects for the definition of the MCI-stable
and AD-converters groups.
MMSE RESULTS
The MMSE score of the MCI-stable group (28± [27:29]) was not
significantly different from the score from AD-converter group
(27 ± [26:28]) at the intake test (permutation test, p = 0.8). At
the follow up approximately 1 year later the stable MCI subjects
remained at a stable MMSE score of 28 ± [26:29], whereas the
MMSE score of the AD-converter group changed to 24 ± [22:24]
(permutation test, p = 0.0044), which is also lower than the sta-
ble MCI group’s MMSE scores (permutation test, p = 0.0002)
(Table 1).
APOE STATUS
We observed a significantly higher frequency of E4 allele vs. no
E4 allele in AD-converter vs. stable MCI (Barnard test, p < 0.01).
Only 38% of MCI-stable compared to 64% of AD-converter
group had more than one E4 allele (Table 2).
SINGLE-BIOMARKER LOGISTIC REGRESSION MODEL OF
AD-CONVERTER vs. MCI-STABLE
To show the principle of logistic regression modeling on a
single biomarker, we chose the beta peak frequency, because
this biomarker showed significantly lower values in MCI (MCI:
17.6 ± [16.8:18.2] Hz, n = 39) compared with the AD-converter
group (AD: 19.6 ± [18.1:21.0] Hz, n = 25) (p < 0.0005) in the
first measurement (Figure 3A), and also significantly lower values
in MCI in the second measurement (MCI: 16.9 ± [16.0:17.8]
Hz, n = 17; AD: 19.3 ± [18.6:20.6] Hz, n = 17, p < 0.005)
(frequency values are averages across the significant channels)
(Figure 3A).
We fitted a logistic regression model to the second EEG mea-
surement (n = 17 in both groups, Figure 3B). The model clas-
sified the second measurements with a sensitivity (SE) of 76%,
76% specificity (SP), 76% positive predictive value (PPV), 0.5
Table 2 | Overview of patient groups.
Patient Age MMSE MMSE Number of
group [years] 1st year 2nd year APOE E4
MCI-stable 67 ± [65:71] 28 ± [27:29] 28 ± [26:29] 15 out of 39
AD-convert 69 ± [67:72] 27 ± [26:28] 24 ± [22:24] 16 out of 25
Difference p = 0.49 p = 0.8 p = 0.0002 p < 0.01
(p-value)
Matthew correlation coefficient (MCC), and a positive likelihood
ratio (PLR) of 3.3. Next, we used this logistic model to retro-
spectively classify the first EEG measurement (Figure 3C). The
classification had a SE of 72%, 59% SP, 53% PPV, 0.3 MCC and a
PLR of 1.8; thus, as expected, a worse classification power (MCI
n = 39, AD n = 25) (Figure 3D).
MULTIPLE-BIOMARKER LOGISTIC REGRESSION MODEL OF
AD-CONVERTER vs. MCI-STABLE
By combining several biomarkers it may be possible to obtain
better classification power than the individual biomarkers alone
(Schoonenboom et al., 2004; Buscema et al., 2007; Lehmann
et al., 2007). However, it is not trivial which combinations of
biomarkers are optimal, because of the high number of possi-
ble combinations. Here, we employ a genetic search approach
and elastic net penalization to assists us in finding these optimal
combinations (see Methods and Materials section).
The best set of biomarkers identified by the genetic search was
(six biomarkers): Amplitude correlations with Cz in Beta (13–
30Hz), Bandwidth of subject-specific Beta frequency, Peak width
of dominant beta peak, range of amplitude values in Beta (13–
30Hz), Ratio between theta and alpha power, and alpha relative
power (normalized with 1–45Hz broadband). The logistic regres-
sion training on this biomarker set using the second EEG data
yielded a SE of 100%, 94% SP, 94% PPV, 0.94 MCC, and PLR of
17 (n = 17 in both groups).
The retrospective testing on first-year data using the classifier
model trained on the second-year data gave a SE of 92%, 85% SP,
79% PPV, 0.75 MCC, and PLR of 6 (MCI-stable, n = 39; AD-
convert, n = 25) (Figures 3F,G; Table 3), which indicates that
even at this very early stage differences between AD-converters
and MCI-stable can be identified. However, since second-year
and first-year data from the same subjects may be strongly cor-
related we also performed a classification test using only subjects
that were not used for training the model (i.e., the subjects
without a second EEG recording). We obtained a good classi-
fication with a SE of 88%, 82% SP, 64% PPV, 0.64 MCC and
a PLR of 4.8 (MCI-stable, n = 22; AD-convert, n = 8), sug-
gesting the diagnostic index can generally be used for these
patient groups. Furthermore, we performed a half-split cross-
validation (1000 iterations), with a SE of 75%, 63% SP, 52%
PPV, 0.37 MCC, and a PLR of 2, an indication of the aver-
age outcome. As expected, the classification powers decrease;
however, this is at least partly explained by the lower n num-
ber. However, the combined classification is still much better
than prediction obtained on the individual biomarkers in the
set (Figures 3E, 4). The best single biomarker in the biomarker
set (based on sensitivity and specificity) was the peak width of
the dominant Beta peak, with a SE of 64%, 62% SP, 52% PPV,
0.24 MCC, and a PLR of 1.7 (MCI-stable, n = 22; AD-convert,
n = 8) (Table 3). The logistic regression fitting coefficients for
the combined solution were; −2.9 for Amplitude correlations
with Cz in Beta, 0.5 for bandwidth of subject specific Beta,
3.4 for Peak width of dominant beta peak, −0.6 for range of
amplitude values in Beta, −2.3 for ratio between theta and
alpha power, and −0.2 for alpha relative power. This means
that the peak width of the dominant beta peak had the greatest
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FIGURE 3 | Integration of multiple biomarkers using logistic regression
improves the prediction of Alzheimer’s disease at the MCI stage. (A) A
significant higher Beta peak frequency is observed in Alzheimer’s disease
converter group (AD) (red) compared with mild cognitive impairment stable
group (MCI) (blue), in both first (left) and second (right) year EEG recording.
(permutation test on median, binomial corrected, ∗∗p < 0.005, ∗∗∗p < 0.0005)
(B) The logistic model is fitted to the second-year EEG recording. (C) The
logistic model is used to predict outcome on the first year EEG recording.
Separation plot of AD vs. MCI. (D) Outcome evaluation of beta peak
frequency using five measures of classification power (warmer is better). SE,
Sensitivity; SP, Specificity; PPV, Positive predictive value; MCC, Matthews
Correlation Coefficient; AUC, area under the receiver operator curve. (E)
Outcome evaluation as in (C), but for the “optimal” biomarker set found
using genetic search. The first six columns are for classification of the
individual biomarkers separately. The last column is the combined
classification outcome. We clearly see that the combined outcome is better
than the classification using the individual biomarkers. 1, Peak width of
dominant beta peak; 2, range of amplitude values in Beta (13–30Hz); 3,
Bandwidth of subject-specific Beta frequency; 4, Ratio between theta and
alpha power; 5, alpha relative power (normalized with 1–45Hz broadband); 6,
Amplitude correlations with Cz in Beta (13–30Hz); (C) Combined logistic
classification using the biomarkers 1, 2, 3, 4, 5, and 6. (F) Logistic curve for
combined classification based on first-year EEG. (G) Separation plot of MCI
vs. AD in first EEG recording using combined classification based on
second-year logistic regression coefficients. Note that the recordings used
for training in F are different from those used for testing in (G).
Table 3 | Overview of classification results [classification based on testing subjects that were not used for training the classifier (MCI-stable,
n = 22; AD-convert, n = 8)].
Model Sensitivity Specificity Positive predictive Matthew correlation Positive likelihood
(%) (%) value (%) coefficient ratio
Genetic search 6 biomarkers 88 82 64 0.64 4.8
Single best biomarker 64 62 52 0.24 1.7
Elastic-net 12 biomarkers 75 86 67 0.59 5.5
influence on the outcome, followed by amplitude correlations
with Cz.
Taken together, our results show that it is possible to obtain
a substantial synergistic effect from the integration of several
biomarkers; however, they also show that it is not trivial to iden-
tify which combination of biomarkers is most optimal. The major
issue with our genetic search is that from run to run we do
not obtain the same solution, because the algorithm finds local
maxima. We, therefore, employed an elastic net penalized logis-
tic regression algorithm. This algorithm uses a penalization of
the weights to optimize the set of biomarkers used for classifi-
cation. The classification outcome from this algorithm is worse
than genetic search optimized logistic regression, with a SE of
75%, 86% SP, 67% PPV, 0.59MCC, and a PLR of 5.5 (MCI-stable,
n = 22; AD-convert, n = 8) (Table 3) based on training on the
second-year EEG and testing on the first-year recording of sub-
jects (the test subjects were not used for training). The elastic net
logistic regression combined 12 biomarkers (non-zero weights),
namely; the amplitude correlations from Cz in Alpha (8–13Hz)
and Beta (13–30Hz), the range of the generalized multifractal
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between the MCI-stable (MCI) and AD-converter (AD) groups, and only
two have longitudinal changes. For each biomarker, a separation plot is
shown for 1st EEG and 2nd EEG. The values are median across channels
with significant differences between the MCI-stable (MCI) and
AD-converter (AD) groups (Binomial corrected). Topographical plots are of
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significant differences (permutation test on median, binomial corrected,
∗p < 0.05, ∗∗p < 0.005).
hurst exponent of the Delta (1–3Hz) amplitude envelope, the
Beta frequency, the power ratio between Gamma (30–45Hz)
and Delta (1–4Hz), Alpha 1 (Individual Alpha frequency-4:
Individual Alpha frequency-2) and Alpha (8–13), Alpha 1 and
Beta (13–30Hz), the spectral edge of the individualized beta-
frequency range, the peak width of the beta peak, the second beta
peak frequency, the stability of the Delta (1–3Hz) frequency mea-
sured in windows of 5 s, and the Hjorth mobility parameter. The
outcome evaluation still shows room for improvement, e.g., by
including biomarkers from other modalities.
DISCUSSION
We addressed the challenge of predicting whether an MCI sub-
ject would convert to AD within 2 years. To this end, we explored
the added value of integrating multiple EEG biomarkers into a
diagnostic index using logistic regression in combination with
either a genetic search or elastic-net penalization for biomarker
selection. From an initial cohort of 86 subjects with mild cog-
nitive impairment, 25 converted to Alzheimer’s disease within 2
years. We showed how data mining of 177 EEG biomarkers could
be used to identify a set of biomarkers that form a diagnostic
index. The analysis was performed using the Neurophysiological
Biomarker Toolbox (NBT, http://www.nbtwiki.net/) (Hardstone
et al., 2012), which is specifically developed to support data min-
ing and integration of large sets of biomarkers. We found that
particularly biomarkers sensitive to changes in the beta frequency
(13–30Hz) band were optimal for classifying the very early EEG
recordings of yet to be diagnosed AD patients.
CLASSIFICATION BASED DIAGNOSTICS
Previous studies have shown promise in using machine-learning
algorithms to classify betweenMCI and AD based on EEG record-
ings (Huang et al., 2000; Bennys et al., 2001; Prichep et al., 2006;
Buscema et al., 2007; Lehmann et al., 2007; Prichep, 2007; Rossini
et al., 2008). A sensitivity of 89% and specificity of 95% were,
e.g., found using the so-called IFASTmodel (Buscema et al., 2007;
Rossini et al., 2008). However, these studies were based on train-
ing and testing on the same data, which makes it more difficult
to judge the performance. Uniquely to the present study, we per-
formed classification training on the second EEG recording, and
retrospectively used this to perform prediction based on the first
EEG recording from subjects not used for the training. We note,
however, that the drawback of the present procedure is the low
number of patients in the smallest patient group (i.e., the eight
patients converting to AD) produced a fairly high error margin to
the classification estimates (12.5%).
OSCILLATIONS ARE INVOLVED IN COGNITION
Empirical and theoretical evidence suggest that oscillations pro-
vide important systems-level mechanisms for normal brain func-
tion (Engel and Singer, 2001; Buzsáki and Draguhn, 2004;
Axmacher et al., 2006; Klimesch et al., 2007; Palva and Palva,
2007, 2012; Lisman, 2010). For example, oscillations are involved
in memory encoding (Raghavachari et al., 2001; Jensen et al.,
2002), and are thought to provide a timing mechanism for spike-
time dependent plasticity (Engel and Fries, 2010). It, therefore,
seem plausible that if oscillations are abnormal in disorders such
as MCI and AD, then cognition is also affected. Apart from rel-
ative Alpha power and the theta/alpha power ratio, which may
reflect early changes toward the well-known slowing of the EEG
in AD (Bennys et al., 2001; Rossini et al., 2006), our optimal set of
biomarkers is derived from the Beta frequency band (13–30Hz).
Beta-band changes have previously been observed in
Alzheimer’s disease, e.g., by a more anterior distribution (Huang
et al., 2000). The larger width of the beta peak and bandwidth
could potentially be linked with a less stable beta frequency,
and, therefore, also a less efficient working memory (Kopell
et al., 2011). Beta oscillations are believed to maintain the
current sensorimotor and cognitive state (Engel and Fries, 2010).
Activity in the beta-frequency range has also traditionally been
linked with motor function. Interestingly, it has been found
that motor performance is impaired in early-stage Alzheimer’s
disease but not in mild cognitive impairment (Sheridan et al.,
2003; Pettersson et al., 2005), which is a potential explanation
of the prominent role of beta-frequency changes in our data.
Motor function, e.g., gait control, is a higher cognitive function
requiring integration of several cognitive functions, as attention,
planning (Hausdorff et al., 2005; Scherder et al., 2007), albeit
unrelated to performance in memory tests (Hausdorff et al.,
2005). Hyperexcitability of the motor cortex has also been
observed in AD (Di Lazzaro et al., 2004), which our finding of
higher beta frequency also suggests.
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EEG BIOMARKERS AS POTENTIAL INDICATORS OF INFLAMMATION
The standard hypothesis of Alzheimer’s disease is the amyloid
cascade hypothesis stating that the cause of Alzheimer’s should
be found in the build up of amyloid and tangles (Hardy and
Selkoe, 2002; Huang and Mucke, 2012). It has been hypoth-
esized that Alzheimer’s disease is initiated by a micro injury,
presumable a vascular event, in the brain with subsequent acti-
vation of inflammatory responses that further leads to initiation
of the amyloid deposition cycle (De la Torre, 2004; Herrup,
2010).
The theta/(lower alpha) power ratio has previously been asso-
ciated with vascular damage in AD (Moretti et al., 2007b), and
the delta (2–4Hz) power has been associated with inflammation
(Babiloni et al., 2009). EEG power and frequency in general has
also been correlated with cerebral perfusion (O’Gorman et al.,
2013), which is known to be reduced in Alzheimer’s disease (De la
Torre, 1999; Kogure et al., 2000; Murray et al., 2011). If we could
detect early-stage changes using EEG, we would have a power-
ful tool that could detect Alzheimer’s disease at a point where
a possible therapy would be most efficient. Mouse models, e.g.,
show that Aβ-42 modifying therapy has limited effect after neu-
rodegeneration has begun (Dubois et al., 2007; Sperling et al.,
2011). Thus, meaning that diagnosing a patient based on neu-
rodegeneration and cognitive decline may already be too late for
a good treatment outcome because the brain damage has already
occurred.
It has also been shown that the build-up of Aβ42 influences
synaptic transmission, and thus, potentially also give rise to fur-
ther effects in the EEG (Palop and Mucke, 2009; Verret et al.,
2012). Further hippocampal injections of amyloid β in rats have
been shown to induce impaired memory performance combined
with reduced hippocampal theta oscillations and less activity in
GABAergic neurons (GABA, gamma-aminobutyric acid) (Villette
et al., 2010). A recent suggestion for a potential improvement
of Alzheimer’s disease symptoms is transcranial direct current
stimulation (tDCS) (Hansen, 2012). This method increased theta
and alpha oscillations together with improved working mem-
ory performance (Zaehle et al., 2010). Interestingly, it has been
suggested these effects may be caused by altered GABA concen-
tration within the stimulated cortex, and potentially by an adjust-
ment of the excitatory/inhibitory balance, which is disturbed in
Alzheimer’s disease (Di Lazzaro et al., 2004; Rossini et al., 2007;
Stagg et al., 2009). This balance may be directly linked to EEG
biomarkers that have been shown sensitive to Alzheimer’s disease
(Montez et al., 2009; Poil et al., 2011, 2012). It thus seems that
EEG biomarkers may be sensitive to underlying pathophysiology
of AD.
OUTLOOK
We here showed that exploratory data mining and integration
of multiple biomarkers might yield many exciting results on the
large databases of neuroscience data build up over the years.
These studies may identify hidden structures (see schematic
Figure 1C) and be beneficial for both pre-clinical and clinical
research. With recent developments in automatic cleaning of
EEG this analysis may potentially be performed immediately after
the recording (Nolan et al., 2010; Mognon et al., 2011). This
together with the non-invasive character of EEG could make a
diagnostic index using EEG biomarkers a powerful tool to sup-
port the early-stage clinical assessment. EEG biomarkers, apart
from being non-invasive and relative inexpensive, have the advan-
tage of monitoring brain activity in real time, and thus potentially
able to identify tiny changes in ongoing cognition. However, we
believe the best diagnostic/prognostic performance is achieved
if EEG biomarkers are combined with information from other
modalities. Future studies should specifically study how the syn-
ergistic information of integrative biomarkers can be improved
further by the incorporation of different classes of biomark-
ers, which could range from cognitive markers (Tabert et al.,
2006), functional connectivity markers (Stam et al., 2006, 2007),
coherence, synchronization, and topographical location mark-
ers (Huang et al., 2000; Stam et al., 2005; Rossini et al., 2006)
to questionnaire data providing quantitative data on the mental
state of the patients during the resting-state EEG recording (Diaz
et al., 2013). Improvement in algorithms used for pre-selecting
biomarkers could, e.g., be based on measures of interrelatedness
between biomarkers or taking scalp topographies into account
as opposed to the averaged channel biomarker values used here.
We believe the Neurophysiological Biomarker toolbox provides
a promising framework for these studies. This could give rise to
a better integrative understanding of biomarkers involved with
Alzheimer’s disease and brain disorders in general (Searls, 2005;
Dubois et al., 2007; Schneider, 2010).
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